• Je něco špatně v tomto záznamu ?

Auer rod-positive acute leukemia with predominantly lymphoid immunophenotype: Report on 11 cases and review of literature

O. Hrusak, J. Stancikova, E. Vodickova, T. Podolska, A. Möricke, A. Attarbaschi, M. Dworzak, Z. Sestakova, P. Svec, MK. Zaliova, I. Janotova, O. Zapletal, E. Mejstrikova, J. Stary

. 2025 ; 72 (1) : e31394. [pub] 20241016

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002905

Grantová podpora
Univerzita Karlova v Praze
European Union and state budget of Czechia
Ministerstvo Zdravotnictví Ceské Republiky

BACKGROUND: Auer rods (AuRs) are prominent intracellular structures found almost exclusively in myeloid cell malignancies, such as acute myeloid leukemia (AML), chronic and juvenile myelomonocytic leukemia and myelodysplastic syndrome. Extremely rare AuRs have been reported in patients with acute lymphoblastic leukemia (ALL) or among ambiguous lineage leukemia patients with a dominantly lymphoblastic immunophenotype. PROCEDURE: We report diagnostic and follow-up data of an international cohort of 11 children suffering from leukemias with AuRs and with significant presence of T and myeloid markers, majority of whom categorized as early T-cell precursor (ETP, n = 7); or T-ALL (ETP status unknown, n = 2), ALAL (acute leukemia of ambiguous lineage, n = 1), and AML reclassified from ALAL (n = 1). We described other diagnostic details and treatment types and responses. Moreover, we summarize previously published data. RESULTS: Among the four patients who started and remained on ALL-type therapy, all were in the first complete remission, whereas both patients who started and remained on AML-type therapy relapsed and died. Of the patients who followed either a combined ALL/AML protocol (Interfant 06) or who switched from one of the two types of therapy to the other, one patient died, and the remaining four were in first complete remission at the most recent follow-up. We also searched for similar cases in the literature and found only three additional children with nonmyeloid leukemia and AuRs and 10 adults with this type of leukemia. CONCLUSIONS: Briefly, ALL- or combined ALL/AML-type therapy may be effective for treating AuR-positive leukemia patients with a lymphoid immunophenotype.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002905
003      
CZ-PrNML
005      
20250206103934.0
007      
ta
008      
250121s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pbc.31394 $2 doi
035    __
$a (PubMed)39415351
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hrusak, Ondrej $u CLIP, Charles University, Prague, Czech Republic $u Department of Pediatric Hematology and Oncology, Motol Hospital, Prague, Czech Republic $1 https://orcid.org/0000000276111335 $7 xx0036691
245    10
$a Auer rod-positive acute leukemia with predominantly lymphoid immunophenotype: Report on 11 cases and review of literature / $c O. Hrusak, J. Stancikova, E. Vodickova, T. Podolska, A. Möricke, A. Attarbaschi, M. Dworzak, Z. Sestakova, P. Svec, MK. Zaliova, I. Janotova, O. Zapletal, E. Mejstrikova, J. Stary
520    9_
$a BACKGROUND: Auer rods (AuRs) are prominent intracellular structures found almost exclusively in myeloid cell malignancies, such as acute myeloid leukemia (AML), chronic and juvenile myelomonocytic leukemia and myelodysplastic syndrome. Extremely rare AuRs have been reported in patients with acute lymphoblastic leukemia (ALL) or among ambiguous lineage leukemia patients with a dominantly lymphoblastic immunophenotype. PROCEDURE: We report diagnostic and follow-up data of an international cohort of 11 children suffering from leukemias with AuRs and with significant presence of T and myeloid markers, majority of whom categorized as early T-cell precursor (ETP, n = 7); or T-ALL (ETP status unknown, n = 2), ALAL (acute leukemia of ambiguous lineage, n = 1), and AML reclassified from ALAL (n = 1). We described other diagnostic details and treatment types and responses. Moreover, we summarize previously published data. RESULTS: Among the four patients who started and remained on ALL-type therapy, all were in the first complete remission, whereas both patients who started and remained on AML-type therapy relapsed and died. Of the patients who followed either a combined ALL/AML protocol (Interfant 06) or who switched from one of the two types of therapy to the other, one patient died, and the remaining four were in first complete remission at the most recent follow-up. We also searched for similar cases in the literature and found only three additional children with nonmyeloid leukemia and AuRs and 10 adults with this type of leukemia. CONCLUSIONS: Briefly, ALL- or combined ALL/AML-type therapy may be effective for treating AuR-positive leukemia patients with a lymphoid immunophenotype.
650    _2
$a mladiství $7 D000293
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a následné studie $7 D005500
650    12
$a imunofenotypizace $7 D016130
650    _2
$a akutní myeloidní leukemie $x patologie $x terapie $x imunologie $7 D015470
650    _2
$a akutní lymfatická leukemie $x patologie $x terapie $x imunologie $7 D054198
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stancikova, Jitka $u CLIP, Charles University, Prague, Czech Republic $u Department of Pediatric Hematology and Oncology, Motol Hospital, Prague, Czech Republic $1 https://orcid.org/0000000310593404
700    1_
$a Vodickova, Elena $u Department of Clinical Hematology, Motol Hospital, Prague, Czech Republic
700    1_
$a Podolska, Tereza $u CLIP, Charles University, Prague, Czech Republic $u Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic $1 https://orcid.org/0009000198632318
700    1_
$a Möricke, Anja $u Department of Paediatrics, University Medical Centre Schleswig-Holstein, Campus Kiel, Kiel, Germany
700    1_
$a Attarbaschi, Andishe $u St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria $u Department of Pediatrics and Adolescent Medicine, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000292856898
700    1_
$a Dworzak, Michael $u St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria $u Department of Pediatrics and Adolescent Medicine, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000281751097
700    1_
$a Sestakova, Zuzana $u Department of Laboratory Medicine, National Institute of Children's Diseases, Bratislava, Slovakia $1 https://orcid.org/0000000332290404
700    1_
$a Svec, Peter $u Department of Pediatric Hematology and Oncology, National Institute of Children's Diseases, Comenius University, Bratislava, Slovakia $1 https://orcid.org/0000000328892656 $7 jx20110506018
700    1_
$a Zaliova, Marketa Kubricanova $u CLIP, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000216397124 $7 xx0074371
700    1_
$a Janotova, Iveta $u Department of Pediatric Hematology and Oncology, Motol Hospital, Prague, Czech Republic
700    1_
$a Zapletal, Ondrej $u Department of Pediatric Hematology and Biochemistry, University Hospital and Masaryk University Brno, Brno, Czech Republic $1 https://orcid.org/0000000330097491
700    1_
$a Mejstrikova, Ester $u CLIP, Charles University, Prague, Czech Republic $u Department of Pediatric Hematology and Oncology, Motol Hospital, Prague, Czech Republic $1 https://orcid.org/0000000151694653
700    1_
$a Stary, Jan $u Department of Pediatric Hematology and Oncology, Motol Hospital, Prague, Czech Republic $1 https://orcid.org/0000000268187743 $7 jn19990009994
773    0_
$w MED00181047 $t Pediatric blood & cancer $x 1545-5017 $g Roč. 72, č. 1 (2025), s. e31394
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39415351 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206103930 $b ABA008
999    __
$a ok $b bmc $g 2262977 $s 1238912
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 72 $c 1 $d e31394 $e 20241016 $i 1545-5017 $m Pediatric blood & cancer $n Pediatr Blood Cancer $x MED00181047
GRA    __
$p Univerzita Karlova v Praze
GRA    __
$p European Union and state budget of Czechia
GRA    __
$p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace